A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis - PubMed (original) (raw)
. 1981 Jul 1;48(1):198-206.
doi: 10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v.
A Auquier, G Dighiero, C Chastang, H Piguet, J Goasguen, G Vaugier, G Potron, P Colona, F Oberling, M Thomas, G Tchernia, C Jacquillat, P Boivin, C Lesty, M T Duault, M Monconduit, S Belabbes, F Gremy
- PMID: 7237385
- DOI: 10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis
J L Binet et al. Cancer. 1981.
Abstract
Survivals of two series of CLL patients (99 from a retrospective series and 196 from a prospective series) were studied separately. The three main staging systems (Rai, Binet, Rundles) agreed well, but as far as survival is concerned, too many stages are defined. The authors performed a Cox multivariate analysis of survival in order to isolate important prognostic factors at diagnosis and to use them to build a simple three-stage classification. Thrombopenia and anemia appeared as the most important risk factors. Among the nonanemic and nonthrombopenic patients, the number of involved areas was clearly related to prognosis in the authors' two series. This study allowed the authors to propose a new classification in three prognostic groups. Group C: anemia (Hb less than 10 g) and/or thrombopenia (platelets less than 100,000/mm3); about 15% of the patients; median of 2 years. Group B: no anemia, no thrombopenia, three or more involved areas (counting as one each of the following: axillary, cervical, inguinal, lymph nodes, whether unilateral or bilateral, spleen and liver); about 30% of patients; median of 7 years. Group A: no anemia, no thrombopenia, less than three involved areas; about 55% of patients; the survival of this group does not seem different from that of the French population of the same age and sex distribution. This three-stage classification only requires clinical examination and routine hemogram, has a good prognostic value which was confirmed on the series of Montserrat and Rozman (146 patients), and should therefore be helpful in planning new clinical trials.
Similar articles
- Critical discussion of the assessment of a three-stage prognostic classification for chronic lymphocytic leukemia.
Chastang C, Travade P, Auquier A. Chastang C, et al. Stat Med. 1985 Jul-Sep;4(3):287-93. doi: 10.1002/sim.4780040307. Stat Med. 1985. PMID: 3903908 Clinical Trial. - [Clinical staging and course of chronic lymphatic leukemia].
Graf C, Graf-Würmli M, Streuli R, Rhyner K. Graf C, et al. Schweiz Med Wochenschr. 1982 Nov 13;112(46):1652-7. Schweiz Med Wochenschr. 1982. PMID: 7156961 German. - Chronic lymphocytic leukemia. A review of 745 cases and assessment of clinical staging.
Skinnider LF, Tan L, Schmidt J, Armitage G. Skinnider LF, et al. Cancer. 1982 Dec 15;50(12):2951-5. doi: 10.1002/1097-0142(19821215)50:12<2951::aid-cncr2820501241>3.0.co;2-s. Cancer. 1982. PMID: 7139586 - Bone marrow biopsy in chronic lymphocytic leukemia: a review of its prognostic importance.
Montserrat E, Rozman C. Montserrat E, et al. Blood Cells. 1987;12(2):315-26. Blood Cells. 1987. PMID: 3304470 Review. - Prognostic factors in chronic lymphocytic leukemia.
Hallek M, Kuhn-Hallek I, Emmerich B. Hallek M, et al. Leukemia. 1997 Apr;11 Suppl 2:S4-13. Leukemia. 1997. PMID: 9178831 Review.
Cited by
- Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs.
Urso A, Martino EA, Cuneo A, Gentile M, Rigolin GM. Urso A, et al. Cancers (Basel). 2024 Jul 31;16(15):2732. doi: 10.3390/cancers16152732. Cancers (Basel). 2024. PMID: 39123460 Free PMC article. Review. - An overview of prognostic markers in patients with CLL.
Braish J, Cerchione C, Ferrajoli A. Braish J, et al. Front Oncol. 2024 May 16;14:1371057. doi: 10.3389/fonc.2024.1371057. eCollection 2024. Front Oncol. 2024. PMID: 38817892 Free PMC article. Review. - Potential New Therapies "ROS-Based" in CLL: An Innovative Paradigm in the Induction of Tumor Cell Apoptosis.
Sciaccotta R, Gangemi S, Penna G, Giordano L, Pioggia G, Allegra A. Sciaccotta R, et al. Antioxidants (Basel). 2024 Apr 17;13(4):475. doi: 10.3390/antiox13040475. Antioxidants (Basel). 2024. PMID: 38671922 Free PMC article. Review. - The role of polymorphic cytochrome P450 gene (CYP2B6) in B-chronic lymphocytic leukemia (B-CLL) incidence and outcome among Egyptian patients.
Al-Adl M, Youssef MM, El-Sebaie A, Refaat S, El-Said A. Al-Adl M, et al. Oncol Res. 2024 Mar 20;32(4):785-797. doi: 10.32604/or.2024.047021. eCollection 2024. Oncol Res. 2024. PMID: 38560574 Free PMC article.
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical